By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Business Jump for Hungarian Startups and ScaleUps– Expert Speed dating (Loffice Budapest and ABA)

    16.06.2021/ 9.00am (CET), Online Conference

  • Smart Manufacturing and Artificial Intelligence in Austria

    5.08.2021/15.00 CST (China Standard Time), Virtual Event

Austria Map

Find the perfect location for your company

Investments in research and innovation are the basis of success for our company. The business location of Austria offers us an attractive environment of development funding, non-university research facilities and access to optimally trained engineers and university progrlammes“, states Markus Staeblein, Managing Director of NXP Austria GmbH.

NXP Semiconductors Austria GmbH

Logo: NXP Semiconductors Austria GmbH
More testimonials

news from the business location Austria

"There’s just no room for nostalgia or clinging to the way things have been."

Chris Messina (Product developer for Google & Uber and the inventor of the hashtag) on the culture of failure, Silicon Valley and why "that's how it has always been done" might be a dangerous mindset. Interview by Marianna Bonechi (ABA Consultant San Francisco).

Bosch successfully pushes ahead with innovations in Austria

As a leading global supplier of technology and services, the Bosch Group offers technology that is “invented for life”. Thanks to its products and services that are innovative and spark enthusiasm, Bosch improves the quality of life for people worldwide. The innovative strength of the company is the basis for future growth.

More news All blog posts